Research programme: RNA-enabled T-cell therapies - Geneius Biotechnology
Alternative Names: SMAR-T™ cells - Geneius BiotechnologyLatest Information Update: 28 Apr 2023
At a glance
- Originator GENEIUS
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer